Other Liabilities, Noncurrent of NovaBridge Biosciences from 30 Sep 2020 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD and CNY
Description
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
Summary
NovaBridge Biosciences quarterly Other Liabilities, Noncurrent in USD history and change rate from 30 Sep 2020 to 31 Dec 2024.
  • NovaBridge Biosciences Other Liabilities, Noncurrent for the quarter ending 31 Dec 2024 was $0, a 100% decline year-over-year.
NovaBridge Biosciences quarterly Other Liabilities, Noncurrent in CNY history and change rate from 30 Sep 2020 to 31 Dec 2024.
  • NovaBridge Biosciences Other Liabilities, Noncurrent for the quarter ending 31 Dec 2023 was ¥69,664,000, a 311% increase year-over-year.
Source SEC data
View on sec.gov
Other Liabilities, Noncurrent, Quarterly (USD)
Other Liabilities, Noncurrent, YoY Quarterly Change (%)
Other Liabilities, Noncurrent, Quarterly (CNY)
Other Liabilities, Noncurrent, YoY Quarterly Change (%)

NovaBridge Biosciences Quarterly Other Liabilities, Noncurrent (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $0 -$106,000 -100% 31 Dec 2024 20-F 03 Apr 2025 2024 FY
Q4 2023 $106,000 -$2,353,000 -96% 31 Dec 2023 20-F 03 Apr 2025 2024 FY
Q4 2022 $2,459,000 +$116,000 +5% 31 Dec 2022 20-F 01 May 2023 2022 FY
Q2 2022 $2,082,000 30 Jun 2022 6-K 10 Nov 2022 2022 Q2
Q4 2021 $2,343,000 +$968,000 +70% 31 Dec 2021 20-F 29 Apr 2022 2021 FY
Q4 2020 $1,375,000 31 Dec 2020 20-F 28 Apr 2021 2020 FY
Q3 2020 $1,242,000 30 Sep 2020 6-K 05 Feb 2021 2020 Q3

NovaBridge Biosciences Quarterly Other Liabilities, Noncurrent (CNY)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2023 ¥69,664,000 +¥52,701,000 +311% 31 Dec 2023 20-F 30 Apr 2024 2023 FY
Q4 2022 ¥16,963,000 +¥2,029,000 +14% 31 Dec 2022 20-F 30 Apr 2024 2023 FY
Q2 2022 ¥13,948,000 30 Jun 2022 6-K 10 Nov 2022 2022 Q2
Q4 2021 ¥14,934,000 +¥5,959,000 +66% 31 Dec 2021 20-F 01 May 2023 2022 FY
Q4 2020 ¥8,975,000 31 Dec 2020 20-F 29 Apr 2022 2021 FY
Q3 2020 ¥8,433,000 30 Sep 2020 6-K 05 Feb 2021 2020 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.